TrialCurveRADICALS-RT (long-term follow-up): reconstructed Kaplan–Meier curves
Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Ann Oncol. Author manuscript; Available in PMC 2024 Dec 10. |
|---|---|
| DOI | 10.1016/j.annonc.2024.03.010 |
| Registry | NCT00541047 |
| Phase | Phase 3 |
| Conditions | Gastrointestinal Complications, Prostate Cancer, Sexual Dysfunction, Urinary Complications |
| Interventions | bicalutamide, goserelin acetate, leuprolide acetate, adjuvant therapy, quality-of-life assessment, radiation therapy |
| Sponsor | University College, London |
| Enrolment | 4236 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival
From figure panel · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Salvage RT not reached; Adjuvant RT not reached. Survival at 3 years: Salvage RT 98%; Adjuvant RT 98%. Hazard ratio Salvage RT vs Adjuvant RT 0.98 (95% CI 0.67–1.44).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Salvage RT | 699 | 53 | not reached |
| Adjuvant RT | 697 | 52 | not reached |
- Salvage RT vs Adjuvant RT: reconstructed HR 0.98 (95% CI 0.67–1.44)
Landmark survival (reconstructed)
| Time | Salvage RT | Adjuvant RT |
|---|---|---|
| 1 yr | 100.0% | 99.6% |
| 2 yr | 99.6% | 98.8% |
| 3 yr | 98.4% | 98.1% |
| 5 yr | 96.1% | 96.1% |
| 7 yr | 94.8% | 93.8% |
| 10 yr | 87.9% | — |
Checks against the published figure
- Salvage RT events: printed 53, reconstructed 53 pass
- Salvage RT n: printed 699, reconstructed 699 pass
- Adjuvant RT events: printed 52, reconstructed 52 pass
- Adjuvant RT n: printed 697, reconstructed 697 pass
Biochemical progression-free survival
From figure panel · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Salvage RT not reached; Adjuvant RT not reached. Survival at 2 years: Salvage RT 96%; Adjuvant RT 96%. Hazard ratio Salvage RT vs Adjuvant RT 1.01 (95% CI 0.79–1.29).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Salvage RT | 699 | 131 | not reached |
| Adjuvant RT | 697 | 125 | not reached |
- Salvage RT vs Adjuvant RT: reconstructed HR 1.01 (95% CI 0.79–1.29)
Landmark survival (reconstructed)
| Time | Salvage RT | Adjuvant RT |
|---|---|---|
| 1 yr | 99.1% | 98.1% |
| 2 yr | 96.3% | 95.8% |
| 3 yr | 92.2% | 92.2% |
| 5 yr | 85.4% | 85.8% |
| 7 yr | 82.1% | 81.3% |
Checks against the published figure
- Salvage RT events: printed 131, reconstructed 131 pass
- Salvage RT n: printed 699, reconstructed 699 pass
- Adjuvant RT events: printed 125, reconstructed 125 pass
- Adjuvant RT n: printed 697, reconstructed 697 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/radicals-rt-long-term-follow-up-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/radicals-rt-long-term-follow-up-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Ann Oncol. Author manuscript; Available in PMC 2024 Dec 10. doi:10.1016/j.annonc.2024.03.010. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/radicals-rt-long-term-follow-up
Report a problem with these data
Related trials
- RADICALS-HD (three-way comparison): Freedom from distant metastasis; Metastasis-free survival; Overall survival; Time to salva
- Aglatimagene besadenovec + radiotherapy in prostate cancer: Disease-free survival; Prostate cancer-specific disease-free survival
- STAMPEDE (radiotherapy to the primary tumor): Failure-free survival; Overall survival
- AMPLITUDE: Investigator-assessed radiographic progression-free survival; Overall survival; Radiograph
- CLEAR (Japanese subgroup): Progression-free survival (independent imaging review per RECIST v1.1)
- ESCAPE (metastatic renal cell carcinoma): 1st-line (+ 2nd-line) progression-free survival; 2nd-line progression-free survival; Overa
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials